Evogene Announces Establishment of Ag-Biologicals Subsidiary - LaVie Bio Ltd.

以色列生物技术公司 Evogene 宣布成立农业生物制剂子公司 La Vie

2019-02-27 08:10:00 BioSpace

本文共1128个字,阅读需3分钟

Evogene Ltd. , a leading biotechnology company developing novel products for life science markets, announced today the establishment of a new subsidiary – LaVie Bio Ltd . The new company will focus on improving food quality, agriculture sustainability and productivity through the introduction of novel microbiome based ag-biological products. Evogene's ag-biological assets, capabilities and pipeline focusing on the discovery, optimization and development of sustainable ag-biological products are being transferred to the new subsidiary, along with access to Evogene's Computational Predictive Biology ('CPB') platform. In addition, Evogene's existing co-development collaboration with Corteva, the agricultural division of DowDupont, in the field of corn bio-stimulants will be transferred to LaVie. The assets and capabilities being transferred to LaVie, are a result of Evogene's Ag-Biologicals division's activity initiated in 2015, and include a substantial pipeline focusing on bio-stimulant and bio-pesticide product programs. LaVie's microbiome based product candidate pipeline addresses major needs in row crops such as corn and wheat as well as specialty crops such as vineyards. This pipeline, with its promising results, was established through the use of Evogene's CPB platform, a well-established disruptive technology harnessing the power of Big Data and advanced computational capabilities. LaVie's senior management consists of the previous division managers with Ido Dor, previously the Ag-Biologicals division General Manager and Evogene EVP, now appointed as LaVie Chief Executive Officer. Ofer Haviv, Evogene's CEO, will serve as chairman of the board of directors of the new subsidiary. As Evogene has previously reported, in order to take full advantage of its broadly applicable CPB platform, Evogene focuses on a number of life science based industries in which its technology can serve as the key differentiator in the development of next generation products. Evogene's strategy is to establish focused subsidiaries in each of these selected market areas – such as ag-biologicals – with both full corporate capabilities and continuing access to Evogene's CPB platform. In addition, each of these subsidiaries will have the right to pursue their own business strategy and secure their own financial resources in the future. Ido Dor, LaVie CEO stated: "I am honored to receive the leadership of LaVie and excited by the opportunity to lead LaVie's dedicated multidisciplinary team in the exciting journey of improving food quality and agriculture sustainability. With our strong pipeline and powerful technology, we are confident that this new structure will allow us to extend and accelerate our product development and commercialization efforts." Ofer Haviv, Evogene's President and CEO stated: "I am very pleased with the establishment of our ag-biologicals subsidiary – LaVie, which is another step in the execution of our corporate strategy. I believe this standalone structure will accelerate our product development and commercialization efforts. Led by Mr. Ido Dor and his talented management and scientific team, I look forward to our progress toward commercialization of novel microbiome based ag-biologicals."
Evgene 有限公司,一家领先的生物技术公司,为生命科学市场开发新产品,今天宣布成立一个新的子公司- LaVie 生物有限公司。新公司将通过推出基于微生物组的新型 ag 生物产品,重点提高食品质量、农业可持续发展能力和生产力。 Evgene 的 ag-biology 资产、能力和管道的重点是可持续 ag-biology 产品的发现、优化和开发,随着 Evgene 的计算预测生物学( CPB )平台的进入,这些资产、能力和管道正在转移到新的子公司。此外, Evgene 目前与 DowDupont 农业部门 Corteva 在玉米生物兴奋剂领域的合作开发将转移到 LaVie 。 本次转让给 LaVie 的资产和能力,系 Evgene 公司 Ag-Biologicals 分部2015年启动的活动所致;包括以生物兴奋剂和生物农药产品方案为重点的实质性管道。 LaVie 基于微生物的产品候选管道解决了诸如玉米、小麦等农作物以及葡萄园等特种作物的主要需求。利用 Evgene 公司的 CPB 平台,利用大数据的力量和先进的计算能力,建立了一种成熟的破坏性技术。 LaVie 的高级管理层由以前的部门经理 Ido Dor 组成,以前是 Ag-Biologicals 部门总经理,现在任命 Evgene EVP 为 LaVie 首席执行官。Evgene 的首席执行官 Ofer Haveiv 将担任新子公司的董事会主席。 正如 Evgene 之前所报道的,为了充分利用其广泛适用的 CPB 平台, Evgene 侧重于一些生命科学行业,在这些行业中,其技术可以作为下一代产品开发的关键区别因素。Evgene 的战略是在每个选定的市场领域(如 ag-biologicals )建立重点关注的子公司,同时拥有完全的企业能力和继续使用 Evener 的 CPB 平台。此外,该等附属公司将有权于未来推行其本身的业务策略及取得其本身的财务资源。 LaVie 首席执行官 Ido Dor 表示:“我很荣幸能获得 LaVie 的领导,并对有机会领导 LaVie 致力于多学科的团队在改善食品质量和农业可持续发展的激动人心之旅感到兴奋。凭借我们强大的管道和强大的技术,我们相信这一新结构将使我们能够扩展和加快我们的产品开发和商业化努力。” Evgene 的总裁兼首席执行官 Ofer Haveiv 说:“我非常高兴我们的 ag 生物制剂子公司 LaVie 的成立,这是我们公司战略执行的另一步。我相信这个独立的结构将加速我们的产品开发和商业化努力。在 Ido Dor 先生和他有才能的管理和科学团队的领导下,我期待着我们在新型微生物群 ag 生物制剂商业化方面取得进展。”

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文